Selank
A synthetic peptide associated with anxiolytic and cognitive-interest discussions in nootropic communities.
Also appears in: Immune
What has the price actually done?
Daily, exact-comparability offers. Discounts use the terms known on each historical date.
How this history is calculated
Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.
Let the market come to you.
Watch the best market price or one vendor. Get one email when Selank crosses your target, drops, or sets a new tracked low—without daily noise.
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
Primary research area: Cognitive. Also surfaces under Immune for browsing and discovery.
No major aliases are tracked for this profile yet.
No FDA label signal · 10 trials · 68 PubMed results
Current evidence for Selank is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.
Selank has no clinical trials that name it and 68 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What selank is
Selank is a synthetic peptide that appears in nootropic and neuropeptide discussions, often framed around mood, calmness, or cognitive support.
Why it matters
The nootropic peptide category is one of the clearest examples of how the peptide market expands beyond obesity and recovery. Selank gives that category a concrete starting point in the library.
Regulatory context
Selank is not an FDA-approved cognitive or psychiatric peptide treatment in the United States. It should be read as a research-market/nootropic profile.
Practical reading note
Because the nootropic space is especially vulnerable to overstatement, this is a category where careful separation between community interest and clinical evidence matters a lot.